AHR and neoplasm: Here, we identified a novel, mutant-specific Δ133p53α/IDO1/IL4I1/AHR axis that promote tumor progression and aggressiveness, including reduced apoptosis, increased proliferation, and resistance to treatment [26–30, 38, 45–47].